Daniel Hui
About Daniel Hui
Daniel Hui is a Senior Director of Immunology at Asklepios BioPharmaceutical, Inc., with a strong background in translating research into therapeutic drugs. He has held various roles in the biopharmaceutical industry, including positions at Tmunity Therapeutics and Spark Therapeutics, and has a Ph.D. in Molecular Virology from Case Western Reserve University.
Work at Asklepios BioPharmaceutical
Daniel Hui currently serves as Senior Director of Immunology at Asklepios BioPharmaceutical, Inc. (AskBio) in Philadelphia, Pennsylvania. He has held this position since 2022. In this role, he focuses on advancing immunological research and translating findings into therapeutic applications aimed at improving patient outcomes.
Previous Experience at Tmunity Therapeutics
Prior to his current role, Daniel Hui worked at Tmunity Therapeutics Incorporated. He served as Associate Director of Product Characterization and Clinical Assay Development from 2020 to 2021. He also held the position of Senior Scientist in Product Characterization from 2019 to 2020. His work at Tmunity involved developing and characterizing assays critical for clinical applications.
Background in Immunology and Research
Daniel Hui has extensive experience in immunology and therapeutic development. He has studied T cell responses against AAV-vectors in pre-clinical and early Phase I/II clinical trials. His involvement in the development of engineered CAR-T cells for immuno-oncology applications highlights his commitment to advancing cancer therapies.
Education and Expertise
Daniel Hui earned his Ph.D. in Molecular Virology from Case Western Reserve University School of Medicine, completing his studies from 1998 to 2004. He also holds a Bachelor of Science degree in Microbiology from the University of Pittsburgh, where he studied from 1992 to 1996. His educational background underpins his expertise in virology and immunology.
Career Development and Research Contributions
Daniel Hui's career includes significant roles at various institutions, including The Children's Hospital of Philadelphia, where he was a Postdoctoral Fellow and Research Associate from 2005 to 2014. He also worked as a Research Scientist at Spark Therapeutics from 2014 to 2016. His diverse experience contributes to his proficiency in product characterization and clinical assay development.